Shielding patients: new defense against Post-CAR-T infections

NCT ID NCT05952804

Recruiting now Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

Summary

This study is testing whether giving patients antibody replacement therapy (IVIG) can prevent serious bacterial infections after they receive a powerful cancer treatment called CD19 CAR-T cell therapy. CAR-T therapy can leave patients with low antibody levels, making them vulnerable to infections. Researchers will compare infection rates in 150 patients who receive either the antibody treatment or a placebo for up to 4 months after their CAR-T therapy.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

City of Hope Cancer Center
RECRUITING

Duarte, California, 91010, United States

Contact
Fred Hutch/University of Washington Cancer Consortium
RECRUITING

Seattle, Washington, 98109, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Massachusetts General Hospital Cancer Center
RECRUITING

Boston, Massachusetts, 02114, United States

Contact
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States

Contact
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States

Contact
Oregon Health and Science University (OHSU) Knight Cancer Institute
RECRUITING

Portland, Oregon, 97239, United States

Contact

Conditions

Explore the condition pages connected to this study.

HEMATOLOGIC MALIGNANCIES